"Our strategy of diversifying RPX's operations is clearly helping the Company navigate a challenging near term patent environment," said
Summary Results for the Second Quarter of 2016
Total revenue was
- Subscription revenue from patent risk management services - including insurance - was
$63.2 million , compared to$67.6 million in the prior year period. - Discovery services revenue was
$19.3 million . - Fee-related revenue was
$0.6 million , compared to nil in the prior year period.
GAAP net income for the second quarter was
Non-GAAP net income for the second quarter, which excludes stock-based compensation, the amortization of acquired intangibles, fair value adjustments on deferred payment obligations, gains on extinguishment of deferred payment obligations, and realized losses on exchange of short-term investments, and their related tax effects, was
Non-GAAP Adjusted EBITDA less Net Patent Spend, the Company's preferred measure of adjusted pre-tax free cash flow, was
RPX's patent risk management client network included 317 clients, including insurance clients, as of
Net patent acquisition spend during the quarter totaled
As of
Business Outlook
This outlook reflects the Company's current and preliminary view and may be subject to change. Please see the paragraph regarding "Forward-Looking Statements" at the end of this news release.
The Company provided the following business outlook for the third quarter of fiscal 2016:
Subscription and Discovery revenue[1] |
| |
Fee-related revenue |
| |
Total revenue |
| |
Operating income (non-GAAP) |
| |
Net income (non-GAAP) |
| |
Total Adjusted EBITDA (non-GAAP) |
| |
Effective tax rate (non-GAAP) |
37% | |
Weighted-average diluted shares outstanding |
50 million |
The Company provided the following business outlook for the full year 2016:
Subscription revenue[1] |
| |
Discovery revenue |
| |
Fee-related revenue |
| |
Total revenue |
| |
Cost of revenue (non-GAAP) |
| |
SG&A (non-GAAP) |
| |
Operating income (non-GAAP) |
| |
Net income (non-GAAP) |
| |
RPX adjusted EBITDA (non-GAAP) |
| |
Discovery adjusted EBITDA (non-GAAP) |
| |
Total adjusted EBITDA (non-GAAP) |
| |
Net patent spend |
| |
Adjusted EBITDA less net patent spend (non-GAAP) |
| |
Effective tax rate (non-GAAP) |
37% | |
Weighted-average diluted shares outstanding |
51 million |
The Company provided the following supplemental information regarding amortization expense for the full year 2016:
Amortization of patent assets acquired through |
| |
Amortization of patent assets to be acquired during fiscal 2016 |
| |
Total amortization of patent assets |
| |
Amortization of |
| |
Other intangible amortization expenses[2] |
|
The above outlook is forward-looking. Actual results may differ materially. The Company is not able, at this time, to provide a forward-looking reconciliation to GAAP outlook for the non-GAAP financial metric outlook it has provided above for the third quarter and full year 2016 because of the difficulty of estimating certain items that are excluded from the non-GAAP financial metrics, including those items listed in "Use of Non-GAAP Financial Information" below, the effect of which may be significant. Please refer to the information under the caption "Use of Non-GAAP Financial Information" below.
————————
[1] |
Subscription revenue is comprised of revenue generated from membership subscription services, premiums earned, net of ceding commissions, from insurance policies, and management fees related to its insurance business. |
[2] |
RPX excludes amortization expense related to intangible assets (other than patents) acquired in conjunction with the acquisition of businesses from its non-GAAP financial measures. |
Conference Call
RPX management will host a conference call and live webcast for analysts and investors at
The conference call will be webcast and investors will be able to access the webcast and slide presentation from the "Investor Relations" section of the company's website at www.rpxcorp.com. A replay of the webcast will be available online at the aforementioned website following the conclusion of the conference call.
About RPX
As of June 30, 2016, RPX had invested over $2 billion to acquire more than 15,500 US and international patent assets and rights on behalf of nearly 320 clients in eight key sectors: automotive, consumer electronics and PCs, E-commerce and software, financial services, media content and distribution, mobile communications and devices, networking, and semiconductors.
RPX subsidiary Inventus is a leading international discovery management provider focused on reducing the costs and risks associated with the discovery process through the effective use of technology solutions. Inventus has been providing litigation support services to corporate legal departments, law firms and government agencies since 1991.
Use of Non-GAAP Financial Information
This news release dated
To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, management believes that these non-GAAP measures provide useful information about the Company's core operating results and thus are appropriate to enhance the overall understanding of the Company's past financial performance and its prospects for the future. Management is excluding from some or all of its its non-GAAP operating results (1) stock-based compensation expenses (inclusive of related employer payroll taxes), (2) the amortization of acquired intangible assets (other than patents), (3) fair value adjustments on deferred payment obligations, (4) gains on extinguishment of deferred payment obligations, (5) realized losses on exchange of short-term investments, and (6) their related tax effects.
Management uses these non-GAAP measures to evaluate the Company's financial results and trends, allocate internal resources, prepare and approve our annual budget, develop short- and long-term operating plans, assess the health of our business and determine company-wide incentive compensation. Management believes these non-GAAP measures may prove useful to investors who wish to consider the impact of certain items when comparing the Company's financial performance with that of other companies. The adjustments to the Company's GAAP results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends and performance.
There are limitations in using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are adjusted to calculate our non-GAAP financial measures. Management compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in our public disclosures.
The presentation of additional information should not be considered in isolation or as a substitute for or superior to financial results determined in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measure and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
This news release and its attachments contain forward-looking statements within the meaning of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include statements regarding the future financial performance of RPX as well as any statements regarding the Company's strategic and operational plans. The Company's actual results may differ materially from those predicted or implied in these forward-looking statements. Factors that may contribute to such differences include, among others, the Company's ability to maintain an adequate rate of growth, the success of the Company's insurance and discovery management businesses as well as other new initiatives, and the Company's ability to attract new clients and retain existing clients. Forward-looking statements are often identified by the use of words such as, but not limited
to, "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "target," "will," "would," and similar expressions or variations intended to identify forward-looking statements. More information about potential factors that could affect the Company's business and financial results is included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent annual report on Form 10-K and its quarterly reports on Form 10-Q on file and available at the
Contacts: |
|
Investor Relations |
Media Relations |
|
|
|
|
+1 415-445-3233 |
+1 415-852-3180 |
| ||||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended |
Six Months Ended | |||||||||||||||
2016 |
2015 |
2016 |
2015 | |||||||||||||
Revenue |
$ |
83,109 |
$ |
67,551 |
$ |
162,844 |
$ |
150,838 |
||||||||
Cost of revenue |
49,070 |
36,985 |
96,736 |
71,744 |
||||||||||||
Selling, general and administrative expenses |
25,904 |
18,997 |
52,799 |
38,456 |
||||||||||||
Gain on sale of patent assets, net |
— |
(592) |
— |
(592) |
||||||||||||
Operating income |
8,135 |
12,161 |
13,309 |
41,230 |
||||||||||||
Other income (expense), net |
(1,549) |
934 |
256 |
1,055 |
||||||||||||
Income before provision for income taxes |
6,586 |
13,095 |
13,565 |
42,285 |
||||||||||||
Provision for income taxes |
2,436 |
5,065 |
5,178 |
16,224 |
||||||||||||
Net income |
$ |
4,150 |
$ |
8,030 |
$ |
8,387 |
$ |
26,061 |
||||||||
Net income per share: |
||||||||||||||||
Basic |
$ |
0.08 |
$ |
0.15 |
$ |
0.16 |
$ |
0.48 |
||||||||
Diluted |
$ |
0.08 |
$ |
0.14 |
$ |
0.16 |
$ |
0.47 |
||||||||
Weighted-average shares used in computing net income per share: |
||||||||||||||||
Basic |
51,034 |
54,490 |
51,548 |
54,334 |
||||||||||||
Diluted |
51,557 |
55,687 |
52,089 |
55,457 |
| |||||||
Condensed Consolidated Balance Sheets | |||||||
(in thousands) | |||||||
(unaudited) | |||||||
|
| ||||||
Assets |
|||||||
Current assets: |
|||||||
Cash and cash equivalents |
$ |
130,040 |
$ |
94,983 |
|||
Short-term investments |
69,051 |
231,015 |
|||||
Restricted cash |
476 |
701 |
|||||
Accounts receivable, net |
41,714 |
13,905 |
|||||
Prepaid expenses and other current assets |
17,221 |
12,643 |
|||||
Total current assets |
258,502 |
353,247 |
|||||
Patent assets, net |
212,245 |
254,560 |
|||||
Property and equipment, net |
8,033 |
4,733 |
|||||
Intangible assets, net |
63,130 |
1,801 |
|||||
|
160,122 |
19,978 |
|||||
Restricted cash, less current portion |
1,062 |
727 |
|||||
Deferred tax assets |
25,504 |
6,896 |
|||||
Other assets |
8,503 |
16,619 |
|||||
Total assets |
$ |
737,101 |
$ |
658,561 |
|||
Liabilities and stockholders' equity |
|||||||
Current liabilities: |
|||||||
Accounts payable |
$ |
2,964 |
$ |
959 |
|||
Accrued liabilities |
11,456 |
14,842 |
|||||
Deferred revenue |
119,856 |
110,921 |
|||||
Deferred payment obligations |
1,301 |
2,383 |
|||||
Current portion of long-term debt |
5,224 |
— |
|||||
Other current liabilities |
1,587 |
467 |
|||||
Total current liabilities |
142,388 |
129,572 |
|||||
Deferred revenue, less current portion |
3,277 |
4,731 |
|||||
Deferred tax liabilities |
4,837 |
— |
|||||
Long-term debt |
91,660 |
— |
|||||
Other liabilities |
8,410 |
7,779 |
|||||
Total liabilities |
250,572 |
142,082 |
|||||
Stockholders' equity: |
|||||||
Common stock |
5 |
5 |
|||||
Additional paid-in capital |
351,577 |
344,610 |
|||||
Retained earnings |
141,431 |
172,115 |
|||||
Accumulated other comprehensive loss |
(6,484) |
(251) |
|||||
Total stockholders' equity |
486,529 |
516,479 |
|||||
Total liabilities and stockholders' equity |
$ |
737,101 |
$ |
658,561 |
| |||||||
Condensed Consolidated Statements of Cash Flows | |||||||
(in thousands) | |||||||
(unaudited) | |||||||
Six Months Ended | |||||||
2016 |
2015 | ||||||
Operating activities |
|||||||
Net income |
$ |
8,387 |
$ |
26,061 |
|||
Adjustments to reconcile net income to net cash provided by operating activities: |
|||||||
Depreciation and amortization |
85,585 |
69,991 |
|||||
Stock-based compensation |
9,828 |
8,525 |
|||||
Excess tax benefit from stock-based compensation |
(33) |
(1,195) |
|||||
Gain on sale of patent assets, net |
— |
(592) |
|||||
Amortization of premium on investments |
972 |
3,181 |
|||||
Deferred taxes |
198 |
(186) |
|||||
Unrealized foreign currency loss |
1,213 |
— |
|||||
Fair value adjustment on deferred payment obligations |
(1,920) |
(705) |
|||||
Gain on extinguishment of deferred payment obligation |
(463) |
— |
|||||
Realized loss on exchange of short-term investments |
290 |
— |
|||||
Other |
169 |
— |
|||||
Changes in assets and liabilities, net of business acquired: |
|||||||
Accounts receivable, net |
(15,207) |
13,203 |
|||||
Prepaid expenses and other assets |
(1,479) |
(12,097) |
|||||
Accounts payable |
211 |
418 |
|||||
Accrued and other liabilities |
(6,097) |
(4,850) |
|||||
Deferred revenue |
7,379 |
6,314 |
|||||
Net cash provided by operating activities |
89,033 |
108,068 |
|||||
Investing activities |
|||||||
Purchases of investments |
(31,150) |
(137,663) |
|||||
Maturities of investments |
42,590 |
100,548 |
|||||
Sales of investments |
145,925 |
— |
|||||
Business acquisition, net of cash acquired |
(228,453) |
(425) |
|||||
Decrease in restricted cash |
225 |
269 |
|||||
Purchases of property and equipment |
(2,087) |
(1,134) |
|||||
Acquisitions of patent assets |
(36,546) |
(48,936) |
|||||
Proceeds from sale of patent assets |
— |
650 |
|||||
Acquisition of other assets |
— |
(2,500) |
|||||
Net cash used in investing activities |
(109,496) |
(89,191) |
|||||
Financing activities |
|||||||
Repayment of principal on deferred payment obligations |
— |
(935) |
|||||
Proceeds from deferred payment obligations |
— |
6,270 |
|||||
Proceeds from issuance of term debt |
100,000 |
— |
|||||
Payments of debt issuance costs |
(2,003) |
— |
|||||
Repayment of principal on term debt |
(1,250) |
— |
|||||
Proceeds from exercise of stock options |
247 |
4,294 |
|||||
Taxes paid related to net-share settlements of restricted stock units |
(2,048) |
(2,307) |
|||||
Excess tax benefit from stock-based compensation |
33 |
1,195 |
|||||
Payments of capital leases |
(236) |
— |
|||||
Repurchase of common stock |
(39,072) |
(3,541) |
|||||
Net cash provided by financing activities |
55,671 |
4,976 |
|||||
Foreign-currency effect on cash and cash equivalents |
(151) |
— |
|||||
Net increase in cash and cash equivalents |
35,057 |
23,853 |
|||||
Cash and cash equivalents at beginning of period |
94,983 |
78,019 |
|||||
Cash and cash equivalents at end of period |
$ |
130,040 |
$ |
101,872 |
| |||||||||||||||
Reconciliation to Non-GAAP Net Income Per Share | |||||||||||||||
(in thousands, except per share data) | |||||||||||||||
(unaudited) | |||||||||||||||
Three Months Ended |
Six Months Ended | ||||||||||||||
2016 |
2015 |
2016 |
2015 | ||||||||||||
Revenue |
$ |
83,109 |
$ |
67,551 |
$ |
162,844 |
$ |
150,838 |
|||||||
Cost of revenue |
49,070 |
36,985 |
96,736 |
71,744 |
|||||||||||
Amortization of acquired intangible assets[2] |
(586) |
(50) |
(1,044) |
(100) |
|||||||||||
Non-GAAP cost of revenue |
48,484 |
36,935 |
95,692 |
71,644 |
|||||||||||
Selling, general and administrative expenses |
25,904 |
18,997 |
52,799 |
38,456 |
|||||||||||
Stock-based compensation[1] |
(4,976) |
(4,810) |
(9,998) |
(8,802) |
|||||||||||
Amortization of acquired intangible assets[2] |
(1,999) |
(381) |
(3,708) |
(762) |
|||||||||||
Non-GAAP selling, general and administrative expenses |
18,929 |
13,806 |
39,093 |
28,892 |
|||||||||||
Gain on sale of patent assets, net |
— |
(592) |
— |
(592) |
|||||||||||
Non-GAAP operating income |
15,696 |
17,402 |
28,059 |
50,894 |
|||||||||||
Other income (expense), net |
(1,549) |
934 |
256 |
1,055 |
|||||||||||
Fair value adjustment on deferred payment obligation[3] |
— |
(705) |
(1,920) |
(705) |
|||||||||||
Gain on extinguishment of deferred payment obligations[3] |
(463) |
— |
(463) |
— |
|||||||||||
Realized loss on exchange of short-term investments[3] |
188 |
— |
188 |
— |
|||||||||||
Non-GAAP other income (expense), net |
(1,824) |
229 |
(1,939) |
350 |
|||||||||||
Non-GAAP income before provision for income taxes |
13,872 |
17,631 |
26,120 |
51,244 |
|||||||||||
Provision for income taxes |
2,436 |
5,065 |
5,178 |
16,224 |
|||||||||||
Income tax adjustments[4] |
2,383 |
1,410 |
4,095 |
2,700 |
|||||||||||
Non-GAAP provision for income taxes |
4,819 |
6,475 |
9,273 |
18,924 |
|||||||||||
Non-GAAP net income |
$ |
9,053 |
$ |
11,156 |
$ |
16,847 |
$ |
32,320 |
|||||||
Non-GAAP net income per share: |
|||||||||||||||
Basic |
$ |
0.18 |
$ |
0.20 |
$ |
0.33 |
$ |
0.59 |
|||||||
Diluted |
$ |
0.18 |
$ |
0.20 |
$ |
0.33 |
$ |
0.58 |
|||||||
Weighted-average shares used in computing non-GAAP net income per share: |
|||||||||||||||
Basic |
51,034 |
54,490 |
51,548 |
54,334 |
|||||||||||
Diluted |
51,557 |
55,687 |
52,089 |
55,457 |
| |||||||||||||||
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA Less Net Patent Spend | |||||||||||||||
(in thousands) | |||||||||||||||
(unaudited) | |||||||||||||||
Three Months Ended |
Six Months Ended | ||||||||||||||
2016 |
2015 |
2016 |
2015 | ||||||||||||
Net income |
$ |
4,150 |
$ |
8,030 |
$ |
8,387 |
$ |
26,061 |
|||||||
Provision for income taxes |
2,436 |
5,065 |
5,178 |
16,224 |
|||||||||||
Other (income) expense, net |
1,549 |
(934) |
(256) |
(1,055) |
|||||||||||
Stock-based compensation[1] |
4,976 |
4,810 |
9,998 |
8,802 |
|||||||||||
Depreciation and amortization |
41,032 |
35,978 |
85,587 |
69,988 |
|||||||||||
Non-GAAP adjusted EBITDA[5] |
54,143 |
52,949 |
108,894 |
120,020 |
|||||||||||
Net patent spend |
(20,885) |
(20,500) |
(37,134) |
(74,136) |
|||||||||||
Non-GAAP adjusted EBITDA less net patent spend |
$ |
33,258 |
$ |
32,449 |
$ |
71,760 |
$ |
45,884 |
| ||||||||
Additional Metrics | ||||||||
(in thousands, except client data) | ||||||||
(unaudited) | ||||||||
As of and for the Three | ||||||||
Operating Metrics |
2016 |
2015 | ||||||
Number of clients[7] |
317 |
225 |
||||||
Net additions[7] |
31 |
1 |
||||||
Gross patent spend |
$ |
21,115 |
$ |
20,575 |
||||
Net patent spend |
$ |
20,885 |
$ |
20,500 |
||||
As of and for the Three | ||||||||
Financial Metrics |
2016 |
2015 | ||||||
Subscription revenue[6] |
$ |
63,219 |
$ |
67,551 |
||||
Discovery revenue |
19,258 |
— |
||||||
Fee-related revenue |
632 |
— |
||||||
Total revenue |
$ |
83,109 |
$ |
67,551 |
||||
Cash, cash equivalents and short-term investments |
$ |
199,091 |
$ |
381,154 |
||||
Deferred revenue, current and non-current |
$ |
123,133 |
$ |
142,623 |
[1] |
RPX excludes stock-based compensation and related employer payroll taxes from its non-GAAP financial measures. |
[2] |
RPX excludes amortization expense related to intangible assets (other than patents) acquired in conjunction with the acquisition of businesses from its non-GAAP financial measures. |
[3] |
RPX excludes fair value adjustments and gains on extinguishment related to its deferred payment obligations and realized losses on exchanges of short-term investments from its non-GAAP financial measures. |
[4] |
Amount reflects income taxes associated with the above noted non-GAAP exclusions. |
[5] |
RPX calculates non-GAAP adjusted EBITDA as GAAP earnings before other income or expenses, net, taxes, depreciation, amortization, and stock-based compensation expenses (inclusive of related employer payroll taxes). |
[6] |
Subscription revenue is comprised of revenue generated from membership subscription services, premiums earned, net of ceding commissions, from insurance policies, and management fees related to its insurance business. |
[7] |
Represents clients receiving RPX's patent risk management services only; does not include RPX's discovery services clients. |
Logo - http://photos.prnewswire.com/prnh/20130730/SF55756LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rpx-announces-second-quarter-2016-financial-results-300307946.html
SOURCE
News Provided by Acquire Media